erlotinib150mg erlotinib150mg


Erlonat tablets are FDA affirmed item containing a functioning substance known as Erlotinib.
Erlonat is pharmacologically ordered as kinase inhibitor and against neoplastic action.
Erlonat is synthetically named quinazoline subordinate with protein kinase inhibitor for EFGR related tyrosine kinase.

Erlonat works as;

Erlonat comprises of Erlotinib which displays against neoplastic movement by battling with adenosine triphosphate, Erlotinib get blends reversibly to intracellular synergist site of epidermal development factor tyrosine kinase, through restricting EFGR phosphorylation and hinder the flag transduction occasions and tumorigenic action identified with EGFR action.
Erlotinib hinder the signal transduction, this may finishes up as bar of new cell arrangement.

Erlonat ADME properties;;

After oral administration of Erlonat; 60% dose get absorbed quickly. Bioavailability occurs by 100%
High plasma concentration time 4 hours Solubility depends up on pH levels, if pH decreases then solubility of Erlotinib get increases & vice versa.
Plasma protein binding effect of Erlotinib is 93% Volume of distribution is 232L
CYP3A4 is widely used for the metabolism of Erlotinib & CYP1A2 is used in lesser extent.
83% eliminated via feces & 8% via urine. Half lives of Erlotinib are 36.2 hours
Erlotinib undergoes hepatic metabolism



(Anti-neoplastic agent)

Brand : Erlonat
ingredient : Erlotinib
Strength :150mg
Mfg :Natco pharma
Pack :30 tablets in a container

Erlonat indication;

Metastatic non small cell lung cancer
Pancreatic cancer

Erlonat is utilized for treating the metastatic non small cell lung carcinoma; it is appropriate for the patients who are cloister treated with chemotherapy which get fizzled.
Erlonat is utilized as a part of mix with gemcitabine as a first line treatment for pancreatic cancer.

Erlonat dosage;

For pancreatic cancer:
The standard dosage of erlonat for this condition is 100mg ought to be controlled orally by taking with no less than one hour sooner or two hours after take-up of nourishment by consolidating with gemcitabine.
Do not co administered erlonat with gastric regulators, some time interval should be maintained between the administrations of these drugs.
For non small cell lung cancer:
The typical dosage of erlonat in this condition is 150mg ought to be directed orally by taking no less than one hour sooner or two hours after the admission of sustenance.

Dosage change:

1. If there should arise an occurrence of interstitial lung sickness, erlonat tablets ought to be ceased and proper strong measures ought to be started.
2. If there should arise an occurrence of diarrheal condition, loperamide tablet ought to be recommended. In extreme loose bowels, dehydration ought to be happens in this condition Erlonat tablet ought to be hinder or stop.
3. In serious skin responses, Erlonat tablet ought to hinder or suspended. In the event that measurements diminishment is important then the dosage of Erlonat is lessened in 50mg.
4. Erlonat joined with powerful CYP3A4 inhibitors, dose lessening is fundamental. If there should arise an occurrence of mix of Erlonat with CYP3A4 or CYP1A2 inhibitors, measurements decrease is required.
5. Erlonat with CYP3A4 inducers causes diminished AUC of Erlotinib, to maintain a strategic distance from the issue by expanding the dosage of erlonat.
6. Cigarette smoking ought to be abstained from amid the treatment; this may lessen the Erlotinib exposure.
7. The disposal of Erlotinib is significantly happens by means of hepatic digestion and biliary discharge.
In the event of serious hepatic weakened patients, Erlonat tablet ought to be hindered or suspend. The use of Erlotinib ought to be founded on the level of bilirubin. Intrusion of Erlonat tablets ought to be happens, if add up to bilirubin, AST or ALT levels get increment.

Erlonat drug interactions;;

Erlonat + CYP3A4 inhibitor like ketaconazole: Elevation of Erlotinib AUC occurs.
Erlonat + CYP3A4 & CYP1A2 inhibitor like ciprofloxacin: Elevation of Erlotinib exposure & its plasma concentration.
Erlonat + CYP3A4 inducer like rifampin: Reduced Erlotinib exposure
Erlonat + cigarette smoking: Depletion of Erlotinib exposure.

Erlonat + CYP3A4 substrate like Midazolam: Depletion of AUC of Midazolam by 24%.
Erlonat + gastric regulators: Alters the solubility of Erlotinib & depletes the bioavailability of Erlotinib.
Erlonat + proton pump inhibitor: depletes the AUC of Erlotinib by 46%.

Erlonat side effects;

Increased bilirubin
Increased AST & ALT
Dry skin
Abdominal pain

Erlonat warning & precautions;

Pneumonic harmfulness:
In the event of interstitial lung ailment, treatment utilizing with erlonat ought to be put off or ceased.
Give some broad strong measures to the patients.
Hepatic disability;
In extreme disabled condition, treatment ought to hinder or stopped.
Keep the issue by checking the liver capacity test oftentimes
Keep up the hepatic enzymes level.
As often as possible screens the bilirubin level, AST and ALT level.
In serious lethal condition, treatment ought to be ceased.
Renal disappointment;
Occasional observing of renal capacity ought to be kept up
Serum electrolytes level ought to be dissected every now and again and decrease the occurrence of dehydration. In serious condition, treatment ought to be stopped.
Myocardial localized necrosis or ischemia;
Cardiovascular capacities ought to be observed
This unfavorable impact is happens because of simultaneous utilization of erlonat with gemcitabine in pancreatic tumor.
This deadly case is happening amid the blend of erlonat with gemcitabine.
Hemolytic anemia related thrombocytopenia ought to be happens.
Blood counts ought to be as often as possible checked amid the treatment.

Erlonat ought not to be utilized as a part of pregnancy period and prompts cause fetal harm.

If there should arise an occurrence of blend of erlonat with warfarin causes expanded draining impacts which may happens by fluctuating the prothrombin time and INR esteems.

Erlonat is contraindicated to;
Pregnancy & lactation
Some hypersensitivity reactions should be produced due to patients is contraindicated to the ingredient of Erlonat tablets.

Erlonat uses in


Pregnancy category of erlonat is D
Erlonat should not be recommended during pregnancy period.


Breast feeding should not be recommended.


The potency of Erlotinib should not be evaluated for pediatric patients

Erlonat storage

Erlonat tablet should be stored at temperature 25oC (77oF).

Prescription is a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines. will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists

The drug information provided in the is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website. requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from is a Caregiver can order prescription medicines on your behalf.


This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product. ,

Apartment No.304 A Wing,
Shiva Shakthi chs ltd,
           JP Road, Near Apna Bazar,
            Andheri(West), Mumbai - 400058.

+91- 9987711567